CCR5: From natural resistance to a new anti-HIV strategy

Research output: Contribution to journalArticlepeer-review


The C-C chemokine receptor type 5 (CCR5) is a key player in HIV infection due to its major involvement in the infection process. Investigations into the role of the CCR5 coreceptor first focused on its binding to the virus and the molecular mechanisms leading to the entry and spread of HIV. The identification of naturally occurring CCR5 mutations has allowed scientists to address the CCR5 molecule as a promising target to prevent or limit HIV infection in vivo. Naturally occurring CCR5-specific antibodies have been found in exposed but uninfected people, and in a subset of HIV seropositive people who show long-term control of the infection. This suggests that natural autoimmunity to the CCR5 coreceptor exists and may play a role in HIV control. Such natural immunity has prompted strategies aimed at achieving anti-HIV humoral responses through CCR5 targeting, which will be described here.

Original languageEnglish
Pages (from-to)574-600
Number of pages27
Issue number2
Publication statusPublished - Feb 2010


  • CCR5
  • HIV
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Fingerprint Dive into the research topics of 'CCR5: From natural resistance to a new anti-HIV strategy'. Together they form a unique fingerprint.

Cite this